Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesClinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.52 AUD -0.22 ( 2.84%)
Last update at 2026-11-06T05:10:00Z
VOLUME
172451
Market Cap
390.77M
P/E
11.55

Momentum Score

…

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.39
Low
8.30
High
52 Week Price Range
6.62
Low
13.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Clinuvel Pharmaceuticals develops melanocortin-based therapies and commercializes its lead approved product, afamelanotide (SCENESSE), for erythropoietic protoporphyria while advancing programs in vitiligo and other dermatologic indications. Long-term growth may be supported by geographic expansion, label extensions, broader specialist uptake and further clinical progress, and investors may find the company attractive for an established commercial franchise that could support recurring specialty revenues.

Key risks include reliance on one marketed product, clinical and regulatory setbacks for the pipeline, pricing and reimbursement pressure, and manufacturing or intellectual property challenges.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.74
Dividend Yield
0.71%
Revenue TTM
94.02M
Revenue Per Share
1.88
Gross Profit TTM
78.21M
Debt / Equity
0.01
ROE
13.21%
Net Debt
-18.49M
ROCE
14.64%
Diluted EPS TTM
0.67

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 47.66M 51.55M 50.68M 45.58M 34.32M
Net income 33.92M 36.17M 35.64M 30.60M 20.88M
Selling general administrative 11.17M 26.85M 1.74M 22.57M 17.71M
Selling and marketing expenses 8.42M - 23.28M - -
Gross profit 78.21M 79.14M 80.45M 69.53M 55.24M
Reconciled depreciation - 1.18M 1.14M 0.79M 0.76M
Ebit 40.53M 56.02M 55.13M 48.77M 36.60M
Ebitda 41.11M 57.20M 56.28M 49.56M 37.35M
Depreciation and amortization 0.58M 1.18M 1.14M 0.79M 0.76M
Operating income 40.53M 45.73M 48.01M 44.13M 35.55M
Other operating expenses 53.49M 49.28M 39.03M -18.41M -11.07M
Interest expense 0.08M 4.46M 4.45M 3.19M 2.27M
Tax provision - 15.38M 15.04M 14.97M 13.44M
Interest income - 9.43M 7.32M 2.45M 0.44M
Net interest income - 4.97M 2.87M 0.71M -1.83M
Income tax expense 13.74M 15.38M 15.04M 14.97M 13.44M
Total revenue 94.02M 95.02M 88.18M 78.32M 65.72M
Total operating expenses 37.68M 33.40M 31.30M 25.43M 19.91M
Cost of revenue 15.81M 15.88M 7.73M 8.79M 10.48M
Total other income expense net 7.13M 5.82M 2.67M 0.76M 0.82M
Net income from continuing ops - 36.17M 35.64M 30.60M 20.88M
Net income applicable to common shares - 36.17M 35.64M 30.60M 20.88M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 296.15M 271.75M 231.12M 193.71M 143.95M
Intangible assets 0.19M 0.19M 0.19M - -
Other current assets 2.24M 2.58M 1.33M 1.07M 1.04M
Total liab 23.27M 30.94M 28.11M 29.08M 18.39M
Total stockholder equity 272.88M 240.81M 203.01M 164.63M 125.56M
Other current liab 17.55M 24.23M 22.50M 22.70M 13.47M
Common stock 172.31M 169.28M 168.80M 151.85M 151.85M
Capital stock - 169.28M 168.80M 151.85M 151.85M
Retained earnings 95.04M 63.63M 29.96M -9.77M -38.40M
Other liab - - - 2.89M 3.72M
Good will - - - 0.19M 0.19M
Other assets - - - 1.06M 0.48M
Cash 20.43M 224.11M 183.87M 156.81M 121.51M
Total current liabilities 19.22M 27.21M 25.21M 25.49M 13.73M
Current deferred revenue - - - -0.30M -0.32M
Net debt -18.49M -223.58M -182.99M -155.81M -120.25M
Short term debt 0.39M 0.43M 0.37M 0.30M 0.32M
Short long term debt total 1.94M 0.53M 0.88M 1.00M 1.26M
Other stockholder equity - - - -142.08M -113.45M
Property plant equipment - - - 2.85M 2.70M
Total current assets 284.63M 262.97M 222.06M 189.62M 140.58M
Long term investments - 0.21M 0.13M - -
Net tangible assets - - - 164.45M 125.37M
Short term investments 231.62M 196.09M 148.67M 133.93M 98.66M
Net receivables 23.45M 27.46M 26.24M 22.21M 16.20M
Inventory 6.88M 8.82M 10.63M 9.52M 1.83M
Accounts payable 1.28M 2.55M 2.35M 2.79M 0.26M
Accumulated other comprehensive income 5.53M 7.90M 4.25M 22.56M 12.11M
Non currrent assets other 0.22M - - -3.04M -2.89M
Non current assets total 11.52M 8.78M 9.06M 4.10M 3.37M
Capital lease obligations - 0.53M 0.88M 1.00M 1.26M
Long term debt total - - - 0.70M 0.94M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -47.72M -29.03M -1.03M -0.43M
Change to liabilities - - - 3.08M 6.06M
Total cashflows from investing activities -39.12M -47.72M -29.03M -1.03M -0.43M
Net borrowings - - - -0.26M -0.27M
Total cash from financing activities -2.75M -2.94M -3.57M -2.24M -1.50M
Change to operating activities - - - -1.41M -2.53M
Net income 33.92M 36.17M 35.64M 30.60M 20.88M
Change in cash -7.59M -7.18M 3.31M 35.30M 38.82M
Begin period cash flow 28.02M 35.20M 31.89M 121.51M 82.69M
End period cash flow 20.43M 28.02M 35.20M 156.81M 121.51M
Total cash from operating activities 36.91M 41.10M 37.05M 36.91M 39.87M
Issuance of capital stock - 0.19M 4.16M - -
Depreciation 0.99M - 1.14M 0.74M 0.72M
Other cashflows from investing activities - -47.42M -23.46M - -
Dividends paid 2.51M -2.50M -2.47M -1.98M -1.24M
Change to inventory 1.94M 1.81M -1.11M -7.69M 1.35M
Change to account receivables 4.16M -1.22M -4.02M -6.01M -0.11M
Sale purchase of stock -0.56M -0.44M -4.91M - -
Other cashflows from financing activities -0.24M -0.18M -0.35M -0.26M -0.27M
Change to netincome - - - 8.78M 6.32M
Capital expenditures 1.60M 0.30M 5.58M 1.03M 0.43M
Change in working capital -3.26M 2.20M -5.06M -13.70M 1.24M
Stock based compensation - - 6.11M 8.99M 6.12M
Other non cash items 5.27M 38.90M -0.77M 5.57M 18.28M
Free cash flow 35.31M 40.80M 31.48M 35.88M 39.44M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CUV
Clinuvel Pharmaceuticals Ltd		 -0.22
2.84%		 7.52 11.55 11.53 4.16 1.31 1.14 2.65
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

535 Bourke Street, Melbourne, VIC, Australia, 3000

61 3 9660 4900

https://www.clinuvel.com

Name Title Year Born
Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA CEO, MD & Director 1963
Mr. Darren M. Keamy CFO & Company Sec. 1973
Dr. Dennis J. Wright Chief Scientific Officer NA
Mr. Lachlan Hay Director of Global Operations NA
Mr. Malcolm Bull Head of Investor Relations NA
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1963
Mr. Darren Michael Keamy B.Com., CPA CFO & Company Secretary 1973
Mr. Malcolm Bull Head of Australian Operations & Investor Relations NA
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs NA
Dr. Azza Hamila Head of Quality & Drug Safety NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…